1. Precision and Personalized Medicine and anti-TB treatment: Is TDM feasible for programmatic use?

   Alffenaar, J-W. C., Akkerman, O. W., Kim, H. Y., Tiberi, S. & Battista Migliori, G., 1-Mar-2020, In : International Journal of Infectious Diseases. 92, p. S5-S9 5 p.

   Research output: Contribution to journal › Article › Academic › peer-review

2. Should we worry for bedaquiline exposure in the treatment of MDR- and XDR-TB?

   Global Tuberculosis Network Bedaquiline study group, Alffenaar, J-W. C., Akkerman, O. W., Tiberi, S., Sotgiu, G. & Migliori, G. B., 1-Feb-2020, In : European Respiratory Journal. 55, 2, 3 p., 1901908.

   Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

3. Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives

   Global TB Network Clinical Trials, Pontali, E., Raviglione, M. C. & Migliori, G. B., 30-Jun-2019, In : European Respiratory Review. 28, 152, 7 p., 190035.

   Research output: Contribution to journal › Review article › Academic › peer-review

4. Regimen design and pharmacokinetic-pharmacodynamic science: lessons learned

   Alffenaar, J-W. C., Tiberi, S. & Migliori, G. B., Jan-2019, In : Lancet Infectious Diseases. 19, 1, p. 3-4 3 p.

   Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

5. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study

   members of the International Study Group on new anti-tuberculosis drugs and adverse events monitoring, Jun-2019, In : International Journal of Infectious Diseases. 83, p. 72-76 5 p.

   Research output: Contribution to journal › Article › Academic › peer-review

View all (10) »